TrialBone marrow transplantation2017

Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia.

P Tsirigotis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.